Clinical Trials Browser

Phase 3 × INDUSTRY × surufatinib × Clear all

NCT02588170 2023-03-30

Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors

Phase 3 Completed

Neuroendocrine Tumors

NCT02589821 2023-03-30

Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors

Phase 3 Completed

Neuroendocrine Tumors